// App-Quantinova.ai

POS0731 (2022) : ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH TYPE I INTERFERON GENE SIGNATURE FROM THE INTERNATIONAL SYSTEMIC LUPUS ERYTHEMATOSUS PROSPECTIVE OBSERVATIONAL COHORT STUDY (SPOCS)

Researchers

Presenter

  • M. Aringer

Principal Investigators

  • L. Arnaud

  • C. Peschken

  • R. Furie

  • E. F. Morand

  • C. Seo

  • E. Rapsomaniki

  • J. Hedberg

  • J. Knagenhjelm

  • T. Grnfeld En

  • B. Desta

  • R. Tummala

  • A. Sorrentino

  • H. Stirnadel-Farrant

Medical Centers

  • University Medical Center & Faculty of Medicine Carl Gustav Carus, Technical University of Dresden, Division of Rheumatology, Department of Medicine III, Dresden, Germany

  • Hôpital de Hautepierre, Department of Rheumatology, National Reference Centre for Rare Auto-Immune Diseases, Strasbourg, France

  • University of Manitoba, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Canada

  • Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Dermatology, Hempstead, United States of America

  • Monash University, Faculty of Medicine, Nursing & Health Sciences, School of Clinical Sciences, Melbourne, VIC, Australia

  • AstraZeneca Pharmaceuticals, Cambridge, United Kingdom

  • AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden

  • AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden

Locations

  • Germany

  • France

  • Canada

  • United States

  • Australia

  • United Kingdom

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • Interferon

Outcome

  • N/A

Study Design

  • Observational

  • Non Interventional

  • Multinational

  • Prospective

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • AstraZeneca.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved